Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2001
12/27/2001WO2001098455A2 Method for preparing a physiologically active il-18 polypeptide
12/27/2001WO2001098357A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
12/27/2001WO2001098354A2 Human receptors
12/27/2001WO2001098351A2 G-protein coupled receptors
12/27/2001WO2001098350A2 Compositions comprising net-4 modulations and their use for treating neoplastic disease
12/27/2001WO2001098346A2 Methods and compositions for the treatment of peripheral artery disease
12/27/2001WO2001098343A2 Conserved diaphanous-related formin autoregulatory domain (dad)
12/27/2001WO2001098332A2 Secreted redox proteins
12/27/2001WO2001098331A2 Glucagon-like peptide-1 analogs
12/27/2001WO2001098330A2 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS
12/27/2001WO2001098301A1 Pyrazolopyridine compounds and use thereof as drugs
12/27/2001WO2001098299A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents
12/27/2001WO2001098298A1 Indole derivatives useful for the treatment of cns disorders
12/27/2001WO2001098293A1 Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals
12/27/2001WO2001098291A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
12/27/2001WO2001098290A2 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
12/27/2001WO2001098289A1 Novel non-psychotropic cannabinoids
12/27/2001WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use
12/27/2001WO2001098279A2 Bis-arylsulfones
12/27/2001WO2001098278A1 Methods and compositions utilizing quinazolinones
12/27/2001WO2001098277A2 Substituted bicyclic derivatives for the treatment of abnormal cell growth
12/27/2001WO2001098273A1 Novel compounds
12/27/2001WO2001098272A1 Novel compounds
12/27/2001WO2001098271A1 4-substituted piperidine compound
12/27/2001WO2001098270A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
12/27/2001WO2001098268A2 Piperidine amides as modulators of chemokine receptor activity
12/27/2001WO2001098262A1 Amidine derivatives as selective antagonists of nmda receptors
12/27/2001WO2001098256A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
12/27/2001WO2001098253A2 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists
12/27/2001WO2001098250A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
12/27/2001WO2001098248A2 Hiv integrase inhibitors
12/27/2001WO2001097862A2 Stabiliser for radiopharmaceuticals
12/27/2001WO2001097860A2 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
12/27/2001WO2001097858A2 Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
12/27/2001WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/27/2001WO2001097849A1 Antitumor effect potentiators
12/27/2001WO2001097848A2 Vitronectin receptor antagonist pharmaceuticals
12/27/2001WO2001097843A2 Methods for enhancing antibody-induced cell lysis and treating cancer
12/27/2001WO2001097835A1 Matrix protein compositions for inhibition of epithelial cell growth
12/27/2001WO2001097829A2 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
12/27/2001WO2001097821A1 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
12/27/2001WO2001097819A1 Influenza virus binding, sialylated oligosaccharide substance and use thereof
12/27/2001WO2001097811A1 Method for the treatment of overactive bladder
12/27/2001WO2001097810A2 Use of therapeutic benzamide derivatives
12/27/2001WO2001097807A1 New use of angiotensin ii antagonists
12/27/2001WO2001097805A2 Solid valsartan pharmaceutical compositions
12/27/2001WO2001097800A1 Method of stabilizing medicinal compositions containing pravastatin
12/27/2001WO2001097793A2 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
12/27/2001WO2001097790A2 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
12/27/2001WO2001097789A2 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
12/27/2001WO2001097787A2 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
12/27/2001WO2001097751A2 New formulation comprising a betablocker and optionally a cholesterol-lowering agent
12/27/2001WO2001085719A9 Ortho-substituted anthranilic acid amides and their use as medicaments
12/27/2001WO2001077109A3 Sodium salt of an azo derivative of 5-aminosalicylic acid
12/27/2001WO2001070254A9 Use of human not1 and not1a orphan receptors
12/27/2001WO2001064645A3 Derivatives of quinoline as alpha-2 antagonists
12/27/2001WO2001064199A3 Farnesyl protein transferase inhibitor combinations with taxane compounds
12/27/2001WO2001062223A3 Cosmetic preparations containing plant extracts
12/27/2001WO2001060356B1 Method for improving bone modeling and chondrocyte functioning in growing canines
12/27/2001WO2001059088A3 Vector
12/27/2001WO2001057042A3 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
12/27/2001WO2001055116A3 Quinoline derivatives and their use as aurora 2 kinase inhibitors
12/27/2001WO2001053505A3 Herpes virus strains for gene therapy
12/27/2001WO2001053268A3 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
12/27/2001WO2001051608A3 Hybrid cells obtainable from antigen presenting cells
12/27/2001WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity
12/27/2001WO2001046700A3 Sodium channels as targets for amyloid beta
12/27/2001WO2001046256A3 Vesicle trafficking proteins
12/27/2001WO2001045650A3 Cosmetic use of the residues from wine production
12/27/2001WO2001041771A3 Transdermal system containing acetylsalicylic acid for treatment of migraine
12/27/2001WO2001040239A3 Transition metal-cyclopentadienyl-tropane conjugates
12/27/2001WO2001039795A3 Attenuation of fibroblast proliferation
12/27/2001WO2001038532A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
12/27/2001WO2001035975A3 Treatment of subnormal bone mineral density
12/27/2001WO2001032646A3 Sulfonamide derivatives
12/27/2001WO2000064485A3 Specifically targeted catalytic antagonists and uses thereof
12/27/2001WO1999056780A8 Isomer enriched conjugated linoleic acid compositions
12/27/2001US20010056211 Adrenergic blocking agent
12/27/2001US20010056191 Hydantoin-containing glucokinase activators
12/27/2001US20010056184 Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds
12/27/2001US20010056179 Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
12/27/2001US20010056125 Local anesthetic methods and kits
12/27/2001US20010056124 Such as 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol, in free form or as salt to treat organ or tissue allo- or xeno-transplant rejection
12/27/2001US20010056122 Therapies for treating pulmonary diseases
12/27/2001US20010056121 By administering rosemary or sage extracts; carnosic acid, carnosol
12/27/2001US20010056119 Materials and methods for the treatment of depression
12/27/2001US20010056118 Induction of polymerization of tubulin and the stabilization of microtubules in cells by administering to the cancer cells an effective amount of dictyostatin-1 or derivatives or salt
12/27/2001US20010056113 Methods for the inhibition of angiogenesis with 6-amino EM-12
12/27/2001US20010056110 Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes
12/27/2001US20010056100 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases
12/27/2001US20010056099 Method of reducing morbidity and the risk of mortality
12/27/2001US20010056092 Diaminocyclobutene-3,4-dione derivatives, their preparation and use
12/27/2001US20010056082 Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
12/27/2001US20010056078 Novel method for treating gut disorders using polyanionic polyglycosides
12/27/2001US20010056069 Use of collagen for the treatment of degenerative articular processes
12/27/2001US20010056060 Treatment of osteoporsis with EP2/EP4 receptor selective agonists
12/27/2001US20010055745 Method and device for preparing a dental implant by immersion in a culture of mesenchymal cells
12/27/2001US20010055630 Compostion and methods for treating alzheimer's disease and other amyloidoses
12/27/2001US20010055590 Method for enhancing myoblast migration and invasion in the context of gene therapy
12/27/2001US20010055582 Erythropoietin solution preparation
1 ... 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 ... 1564